Literature DB >> 22964133

The distinct contributions of fitness and genetic barrier to the development of antiviral drug resistance.

Matthias Götte1.   

Abstract

The selection of resistance to antiviral drugs depends on multiple parameters, including the genetic barrier that is often broadly defined as the number of mutations required to overcome drug selective pressure. In this review, it is intended to assess the roles of genetic barrier and viral fitness at various stages of the selection process. Several examples in the fields of HIV and HCV drug resistance show that the two parameters are distinct and independent. An analogy to the concept of kinetic versus thermodynamic control of chemical reactions supports a more narrow definition of the genetic barrier as the kinetic obstacle for the generation of genetic changes required to overcome selective pressure.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22964133     DOI: 10.1016/j.coviro.2012.08.004

Source DB:  PubMed          Journal:  Curr Opin Virol        ISSN: 1879-6257            Impact factor:   7.090


  26 in total

Review 1.  Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms.

Authors:  Diarmaid Hughes; Dan I Andersson
Journal:  Nat Rev Genet       Date:  2015-07-07       Impact factor: 53.242

2.  An Evolutionary Model-Based Approach To Quantify the Genetic Barrier to Drug Resistance in Fast-Evolving Viruses and Its Application to HIV-1 Subtypes and Integrase Inhibitors.

Authors:  Kristof Theys; Pieter J K Libin; Kristel Van Laethem; Ana B Abecasis
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

Review 3.  Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use.

Authors:  Sabrina Bagaglio; Caterina Uberti-Foppa; Giulia Morsica
Journal:  Drugs       Date:  2017-07       Impact factor: 9.546

4.  The tripartite virions of the brome mosaic virus have distinct physical properties that affect the timing of the infection process.

Authors:  Robert Vaughan; Brady Tragesser; Peng Ni; Xiang Ma; Bogdan Dragnea; C Cheng Kao
Journal:  J Virol       Date:  2014-03-26       Impact factor: 5.103

5.  Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors.

Authors:  V C Di Maio; V Cento; C Mirabelli; A Artese; G Costa; S Alcaro; C F Perno; F Ceccherini-Silberstein
Journal:  Antimicrob Agents Chemother       Date:  2014-03-03       Impact factor: 5.191

6.  Multiple genetic pathways involving amino acid position 143 of HIV-1 integrase are preferentially associated with specific secondary amino acid substitutions and confer resistance to raltegravir and cross-resistance to elvitegravir.

Authors:  Wei Huang; Arne Frantzell; Signe Fransen; Christos J Petropoulos
Journal:  Antimicrob Agents Chemother       Date:  2013-06-03       Impact factor: 5.191

Review 7.  Insights on recent approaches in drug discovery strategies and untapped drug targets against drug resistance.

Authors:  Ramalingam Peraman; Sathish Kumar Sure; V N Azger Dusthackeer; Naresh Babu Chilamakuru; Padmanabha Reddy Yiragamreddy; Chiranjeevi Pokuri; Vinay Kumar Kutagulla; Santhivardhan Chinni
Journal:  Futur J Pharm Sci       Date:  2021-03-03

Review 8.  Genetic Consequences of Antiviral Therapy on HIV-1.

Authors:  Miguel Arenas
Journal:  Comput Math Methods Med       Date:  2015-06-10       Impact factor: 2.238

9.  The individualized genetic barrier predicts treatment response in a large cohort of HIV-1 infected patients.

Authors:  Niko Beerenwinkel; Hesam Montazeri; Heike Schuhmacher; Patrick Knupfer; Viktor von Wyl; Hansjakob Furrer; Manuel Battegay; Bernard Hirschel; Matthias Cavassini; Pietro Vernazza; Enos Bernasconi; Sabine Yerly; Jürg Böni; Thomas Klimkait; Cristina Cellerai; Huldrych F Günthard
Journal:  PLoS Comput Biol       Date:  2013-08-29       Impact factor: 4.475

10.  Chemical derivatives of a small molecule deubiquitinase inhibitor have antiviral activity against several RNA viruses.

Authors:  Marta J Gonzalez-Hernandez; Anupama Pal; Kofi E Gyan; Marie-Eve Charbonneau; Hollis D Showalter; Nicholas J Donato; Mary O'Riordan; Christiane E Wobus
Journal:  PLoS One       Date:  2014-04-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.